Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?

Han RC, Fry LE, Kantor A, McClements ME, Xue K, MacLaren RE

Open source

DOI
10.1080/21678707.2021.1882300
Published
2021
Container
Expert opinion on orphan drugs
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21678707.2021.1882300,
  title = {Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?},
  author = {Han RC and Fry LE and Kantor A and McClements ME and Xue K and MacLaren RE},
  year = {2021},
  journal = {Expert opinion on orphan drugs},
  doi = {10.1080/21678707.2021.1882300},
  url = {https://doi.org/10.1080/21678707.2021.1882300}
}

RIS

TY  - JOUR
TI  - Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
AU  - Han RC
AU  - Fry LE
AU  - Kantor A
AU  - McClements ME
AU  - Xue K
AU  - MacLaren RE
PY  - 2021
JO  - Expert opinion on orphan drugs
DO  - 10.1080/21678707.2021.1882300
UR  - https://doi.org/10.1080/21678707.2021.1882300
ER  - 

APA

RC, H., LE, F., A, K., ME, M., K, X., & RE, M. (2021). Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?. Expert opinion on orphan drugs. https://doi.org/10.1080/21678707.2021.1882300

Source records